Skip to content

Drug-eluting PTA Balloon Dilatation Catheter in the Treatment of Peripheral Artery Stenosis or Occlusion

Safety and Efficacy of ZENFlow™ Drug-eluting PTA Balloon Dilatation Catheter in the Treatment of Iliac, Femoral and Popliteal Artery Stenosis or Occlusion

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03844724
Enrollment
204
Registered
2019-02-18
Start date
2015-04-10
Completion date
2018-10-22
Last updated
2019-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Femoral Artery Occlusion, Femoral Artery Stenosis, Iliac Artery Occlusion, Iliac Artery Stenosis, Peripheral Arterial Disease, Popliteal Artery Occlusion, Popliteal Artery Stenosis

Keywords

Peripheral Arterial Disease, Drug-eluting PTA Balloon Dilatation Catheter, Late Lumen Loss(6 months)

Brief summary

Clinical study on safety and efficacy of ZENFlow™ drug-eluting PTA balloon dilatation catheter in the treatment of iliac, femoral and popliteal artery stenosis or occlusion

Detailed description

The purpose of this study was to evaluate the safety and efficacy of ZENFlow™ drug-eluting PTA balloon dilatation catheter (paclitaxel 3±1 μg/mm2 balloon surface area) in the treatment of iliac artery, femoral artery and popliteal stenosis or occlusive lesions compared with conventional PTA balloon dilatation catheter.

Interventions

DEVICEZENFlow™ Drug-eluting PTA Balloon Dilatation Catheter

Digital subtraction angiography(DSA)

Digital subtraction angiography(DSA)

Sponsors

Zhejiang Zylox Medical Device Co., Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Aged from 18 to 85 years old, male or female * Subject's target lesions were stenosis and/or occlusion * Subjects were able to understand the purpose of the study, demonstrate full compliance with the program and sign informed consent

Exclusion criteria

* Pregnant woman or who's pregnancy test is positive * Lactation period woman or woman/man with fertility plan

Design outcomes

Primary

MeasureTime frameDescription
Late Lumen Loss at 6 months after operation6 monthsLate Lumen Loss

Secondary

MeasureTime frameDescription
The incidence of major adverse events12 monthsRelated to death of clinical trials
Adverse EventPreoperative、Intraoperative、up to 1 month、3 months、6 months、9 months、12 monthsAdverse medical events, whether or not related to the medical device

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026